NVIDIA Q1 Adds 7.8 Million Shares of Coherent, Increases CoreWeave Stake by 94.5%

KuCoinFlash

Release Time: 05/17/2026 06:32:16

Summary

NVIDIA’s Q1 2026 on-chain data reveals an $18.374 billion investment portfolio, up from $13 billion in 2025. The company increased its CoreWeave stake by 94.5% to 47 million shares, adding $1.78 billion in value. It also acquired 7.8 million shares of Coherent Corp. and 833,000 shares of Generate Biomedicines. Intel remains NVIDIA’s largest holding, with over 214 million shares. These moves align with CEO Jensen Huang’s strategy to support the AI ecosystem. This crypto news underscores NVIDIA’s growing influence across chips, cloud, and biotech.

BlockBeats news: On May 17, according to the latest Form 13F, as of the first quarter of this year, NVIDIA’s proprietary investment portfolio held stocks with a total market value of approximately $18.374 billion, up from $13 billion at the end of 2025, with holdings concentrated in AI ecosystem-related assets (chips, cloud computing power, EDA, optics, networking, and biopharmaceuticals).

Notably, in Q1, NVIDIA increased its stake in CoreWeave by 94.5% to 47 million shares, adding $1.78 billion in value. It also established new positions in Coherent Corp. (7.8 million shares) and Generate Biomedicines (833,000 shares).

Intel remains its largest holding, with over 214 million shares, reflecting Jensen Huang’s strategic initiative to support the entire AI ecosystem, from chips to cloud computing, networking, photonics, and drug discovery.

Source:Show original

Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information. Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.